University Library
  • Login
A gateway to Melbourne's research publications
Minerva Access is the University's Institutional Repository. It aims to collect, preserve, and showcase the intellectual output of staff and students of the University of Melbourne for a global audience.
View Item 
  • Minerva Access
  • Medicine, Dentistry & Health Sciences
  • Melbourne Medical School
  • Psychiatry
  • Psychiatry - Research Publications
  • View Item
  • Minerva Access
  • Medicine, Dentistry & Health Sciences
  • Melbourne Medical School
  • Psychiatry
  • Psychiatry - Research Publications
  • View Item
JavaScript is disabled for your browser. Some features of this site may not work without it.

    Concordance between actual and pharmacogenetic predicted desvenlafaxine dose needed to achieve remission in major depressive disorder: a 10-week open-label study

    Thumbnail
    Download
    published version (192.8Kb)

    Citations
    Scopus
    Web of Science
    Altmetric
    10
    9
    Author
    Bousman, CA; Mueller, DJ; Ng, CH; Byron, K; Berk, M; Singh, AB
    Date
    2017-01-01
    Source Title
    Pharmacogenetics and Genomics
    Publisher
    LIPPINCOTT WILLIAMS & WILKINS
    University of Melbourne Author/s
    Berk, Michael; Ng, Chee; BYRON, KEITH ANDREW; Bousman, Chad; SINGH, AJEET
    Affiliation
    Psychiatry
    Pathology
    Metadata
    Show full item record
    Document Type
    Journal Article
    Citations
    Bousman, C. A., Mueller, D. J., Ng, C. H., Byron, K., Berk, M. & Singh, A. B. (2017). Concordance between actual and pharmacogenetic predicted desvenlafaxine dose needed to achieve remission in major depressive disorder: a 10-week open-label study. PHARMACOGENETICS AND GENOMICS, 27 (1), pp.1-6. https://doi.org/10.1097/FPC.0000000000000253.
    Access Status
    Open Access
    URI
    http://hdl.handle.net/11343/257050
    DOI
    10.1097/FPC.0000000000000253
    Abstract
    BACKGROUND: Pharmacogenetic-based dosing support tools have been developed to personalize antidepressant-prescribing practice. However, the clinical validity of these tools has not been adequately tested, particularly for specific antidepressants. OBJECTIVE: To examine the concordance between the actual dose and a polygene pharmacogenetic predicted dose of desvenlafaxine needed to achieve symptom remission. MATERIALS AND METHODS: A 10-week, open-label, prospective trial of desvenlafaxine among Caucasian adults with major depressive disorder (n=119) was conducted. Dose was clinically adjusted and at the completion of the trial, the clinical dose needed to achieve remission was compared with the predicted dose needed to achieve remission. RESULTS: Among remitters (n=95), there was a strong concordance (Kendall's τ-b=0.84, P=0.0001; Cohen's κ=0.82, P=0.0001) between the actual and the predicted dose need to achieve symptom remission, showing high sensitivity (≥85%), specificity (≥86%), and accuracy (≥89%) of the tool. CONCLUSION: Findings provide initial evidence for the clinical validity of a polygene pharmacogenetic-based tool for desvenlafaxine dosing.

    Export Reference in RIS Format     

    Endnote

    • Click on "Export Reference in RIS Format" and choose "open with... Endnote".

    Refworks

    • Click on "Export Reference in RIS Format". Login to Refworks, go to References => Import References


    Collections
    • Minerva Elements Records [45770]
    • Pathology - Research Publications [399]
    • Psychiatry - Research Publications [1103]
    Minerva AccessDepositing Your Work (for University of Melbourne Staff and Students)NewsFAQs

    BrowseCommunities & CollectionsBy Issue DateAuthorsTitlesSubjectsThis CollectionBy Issue DateAuthorsTitlesSubjects
    My AccountLoginRegister
    StatisticsMost Popular ItemsStatistics by CountryMost Popular Authors